The aim of this study is to compare quality of care and patient experiences in two outpatients follow-up activities: 1) Standard telePRO (fixed interval telePRO follow-up) and 2) Open Access telePRO (patient-initiated telePRO follow-up)
The traditional system of routine outpatient follow-up of chronic disease in secondary care may involve a waste of resources if patients are well. The use of patient-reported outcomes (PRO) could support more flexible, cost-saving follow-up activities. AmbuFlex is a PRO system used in outpatient follow-up in the Central Denmark Region. PRO questionnaires are sent to patients at fixed intervals. The clinicians use the PRO data to decide whether a patient needs a visit or not (standard telePRO). PRO may make patients become more involved in their own care pathway, which may improve their self-management. Better self-management may also be achieved by letting patients initiate contact. The aim of this study is to obtain data on the effects of patient-initiated follow-up (open access telePRO) on resource utilisation, quality of care, and the patient perspective.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
593
In open access, contacts to the outpatient clinic are initiated solely by the patient. Contacts may be in the form of a PRO assessment like in standard telePRO, but at a time decided by the patient via the Danish National Health website "Sundhed.dk".
Standard care: fixed interval telePRO follow-up. Patients receive a questionnaire with individually pre-specified intervals.
Regional Hospital West Jutland
Herning, Central Jutland, Denmark
Number of contacts
Number of contacts includes all contacts with the outpatient clinic in the study follow-up period
Time frame: 18 months
General health will be assessed by items from the SF-36 questionnaire
General health will be measured at baseline and after 18 months.
Time frame: 18 months
Well-being wil be assessed by the WHO-5 Well-being Index
Well-being will be measured at baseline and after 18 months.
Time frame: 18 months
Mortality
Mortality will be measured after 18 months.
Time frame: 18 months
Number of seizures
Difference number of seizures (start - end) and will be measured at baseline and after 18 months.
Time frame: 18 months
Side effects
Side effects will be measured at baseline and after 18 months.
Time frame: 18 months
Health literacy will be assessed by The Health Literacy Questionnaire (sub scale 4, 6, and 9)
Health literacy will be measured at baseline and after 18 months.
Time frame: 18 months
Self-efficacy will be assessed by The General Self-Efficacy Scale
Self-efficacy will be measured at baseline and after 18 months.
Time frame: 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Confidence will be assessed by one item from the Danish Cancer Society PREM (Barometer) Questionnaire
Confidence will be measured at baseline and after 18 months.
Time frame: 18 months
Safety will be assessed by one item from the Danish Cancer Society PREM (Barometer) Questionnaire
Safety will be measured at baseline and after 18 months.
Time frame: 18 months
Satisfaction will be assessed by one item from the Danish Cancer Society PREM (Barometer) Questionnaire
Satisfaction will be measured at baseline and after 18 months.
Time frame: 18 months